Yuichi Sakamori Selected Research

Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)

4/2024	Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade.
9/2023	Outcomes of immune checkpoint inhibitors for postoperative recurrence of non-small cell lung cancer.
8/2023	CD47 polymorphism for predicting nivolumab benefit in patients with advanced non‑small‑cell lung cancer.
2/2023	Yes-associated protein 1 mediates initial cell survival during lorlatinib treatment through AKT signaling in ROS1-rearranged lung cancer.
12/2022	Combination bezafibrate and nivolumab treatment of patients with advanced non-small cell lung cancer.
12/2021	Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer.
1/2021	PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade.
5/2020	A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed or Bevacizumab Plus Pemetrexed for Advanced Non-squamous Non-small Cell Lung Cancer.
1/2020	Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model.
1/2020	Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yuichi Sakamori Research Topics

Disease

46	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2024 - 01/2010
21	Neoplasms (Cancer) 04/2024 - 07/2010
12	Lung Neoplasms (Lung Cancer) 08/2023 - 03/2010
9	Neoplasm Metastasis (Metastasis) 07/2022 - 03/2010
6	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 07/2022 - 05/2010
6	Adenocarcinoma of Lung 09/2017 - 02/2011
3	Disease Progression 05/2020 - 01/2013
3	Brain Neoplasms (Brain Tumor) 09/2013 - 04/2010
2	Malignant Mesothelioma 11/2022 - 07/2012
2	Interstitial Lung Diseases (Interstitial Lung Disease) 10/2017 - 08/2012
2	Pleural Effusion (Pleural Effusions) 09/2011 - 09/2010
2	Chronic Kidney Failure (Chronic Renal Failure) 04/2011 - 05/2010
1	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 01/2021
1	Carcinogenesis 09/2017
1	Hepatitis 08/2017
1	Neutropenia 05/2016
1	Thymoma (Thymic Carcinoma) 05/2016
1	Intracranial Hemorrhages (Intracranial Hemorrhage) 09/2013
1	Pain (Aches) 03/2013
1	Dyspnea (Shortness of Breath) 03/2013
1	Lymphoma (Lymphomas) 01/2013
1	Pneumonia (Pneumonitis) 07/2012
1	Lewis Lung Carcinoma 07/2012
1	Diarrhea 10/2011
1	Nausea 10/2011
1	Anorexia 10/2011
1	Hemorrhage 10/2011
1	Stomatitis 10/2011

Drug/Important Bio-Agent (IBA)

14	ErbB Receptors (EGF Receptor)IBA 01/2017 - 01/2010
11	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2013 - 04/2010
8	Gefitinib (Iressa)FDA Link 09/2012 - 01/2010
7	NivolumabIBA 08/2023 - 01/2017
6	Tyrosine Kinase InhibitorsIBA 02/2023 - 05/2010
6	Pemetrexed (MTA)FDA Link 05/2020 - 03/2011
6	Anaplastic Lymphoma KinaseIBA 01/2020 - 01/2013
4	Bevacizumab (Avastin)FDA Link 05/2020 - 05/2011
4	alectinibIBA 01/2020 - 11/2018
4	CrizotinibIBA 01/2019 - 01/2013
3	Immune Checkpoint InhibitorsIBA 04/2024 - 08/2023
3	Biomarkers (Surrogate Marker)IBA 01/2020 - 10/2011
3	Paclitaxel (Taxol)FDA LinkGeneric 10/2017 - 01/2015
3	Albumin-Bound Paclitaxel FDA Link 10/2017 - 05/2016
3	SolventsIBA 10/2017 - 01/2015
3	Epidermal Growth Factor (EGF)IBA 09/2012 - 04/2010
3	OSI-420IBA 09/2011 - 05/2010
2	Proteins (Proteins, Gene)FDA Link 02/2023 - 01/2020
2	LigandsIBA 12/2022 - 01/2020
2	Carboplatin (JM8)FDA LinkGeneric 05/2020 - 05/2016
2	amrubicinIBA 03/2020 - 05/2010
2	AlbuminsIBA 10/2017 - 07/2016
2	130-nm albumin-bound paclitaxelIBA 10/2017 - 07/2016
2	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 09/2017 - 09/2012
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 09/2013 - 08/2011
2	Phosphotransferases (Kinase)IBA 01/2013 - 04/2010
2	Insulin-Like Growth Factor Binding Protein 3IBA 09/2012 - 10/2011
2	Insulin-Like PeptidesIBA 09/2012 - 10/2011
1	Immunologic Factors (Immunomodulators)IBA 04/2024
1	Immune Checkpoint ProteinsIBA 04/2024
1	Therapeutic UsesIBA 02/2023
1	Verteporfin (Visudyne)FDA Link 02/2023
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 02/2023
1	lorlatinibIBA 02/2023
1	BezafibrateIBA 12/2022
1	Peptides (Polypeptides)IBA 07/2022
1	big gastrinIBA 07/2022
1	S63845IBA 01/2020
1	navitoclaxIBA 01/2020
1	Apoptosis Regulatory ProteinsIBA 01/2020
1	ATP-Binding Cassette Transporters (ABC Transporters)IBA 01/2020
1	saracatinibIBA 01/2019
1	src-Family KinasesIBA 01/2019
1	ceritinibIBA 11/2018
1	locked nucleic acidIBA 01/2017
1	Peptide Nucleic AcidsIBA 01/2017
1	Circulating Tumor DNAIBA 01/2017
1	Monoclonal AntibodiesIBA 09/2013
1	Vinorelbine (Navelbine)FDA LinkGeneric 06/2013
1	PlatinumIBA 06/2013
1	Docetaxel (Taxotere)FDA Link 06/2013
1	Morphine (MS Contin)FDA LinkGeneric 03/2013
1	Formaldehyde (Formol)FDA Link 02/2013
1	ParaffinIBA 02/2013
1	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 01/2013
1	NOC 18IBA 07/2012
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 07/2012
1	Folic Acid AntagonistsIBA 07/2012
1	Antineoplastic Agents (Antineoplastics)IBA 07/2012
1	Nitroglycerin (Dynamite)FDA LinkGeneric 07/2012

Therapy/Procedure

15	Therapeutics 04/2024 - 01/2010
14	Drug Therapy (Chemotherapy) 12/2021 - 09/2010
2	Immunotherapy 12/2022 - 01/2020
2	Aftercare (After-Treatment) 01/2020 - 09/2017
2	Renal Dialysis (Hemodialysis) 04/2011 - 05/2010
1	Cranial Irradiation 07/2022
1	Chemoradiotherapy 03/2020
1	Drug Tapering 05/2016
1	Radiotherapy 09/2013
1	Oral Medicine 03/2013
1	Adjuvant Chemotherapy 01/2013
1	Retreatment 08/2012